Objective: To evaluate the efficacy and safety of three doses of ciclesonide (with or without spacer) in children with persistent asthma. Patients and methods: This was a multicentre, double-blind, placebo-controlled, 12-week study of ciclesonide 40, 80 or 160 mg (once daily pm). Children (6e11 years) were randomised 1:1 to treatment via a metered dose inhaler (MDI) or MDI plus spacer. The primary variable was change from baseline in mean morning peak expiratory flow (PEF). Secondary variables included: time to first lack of efficacy (LOE), asthma control, forced expiratory volume in 1 s (FEV 1 ), asthma symptom score and quality of life (QoL). Safety assessments included: adverse events (AEs), urinary cortisol excretion and body height. Results: In total, 1073 children received treatment. At endpoint, mean morning PEF significantly improved with all doses of ciclesonide vs. placebo. There was no difference over placebo in time to first LOE, but ciclesonide was superior to placebo on asthma control, symptom score, FEV 1 and QoL. There were no differences between the spacer or non- spacer subgroups. The incidences of AEs were comparable between treatment groups (approximately 35%) and there were no between-group differences in body height or urinary cortisol. Conclusions: Ciclesonide 40e160 mg once daily is effective and well tolerated in children with persistent asthma; its efficacy and safety are unaffected by the use of a spacer. clinicaltrials.gov registration number: NCT00384189. ª
Introduction
Childhood asthma causes considerable morbidity worldwide and is the most prevalent chronic disease in children. 1 Global Initiative for Asthma (GINA) guidelines recommend inhaled corticosteroid (ICS) monotherapy as first-line treatment for patients older than 5 years. 2 The latest guidelines from the National Heart, Lung, and Blood Institute reinforce this, specifying that ICSs are the most potent and consistently effective long-term control medication for asthma in children. 3 These recommendations are based on extensive data from randomised trials in children, which demonstrate that ICSs significantly improve asthma symptoms, increase asthma-free days, reduce the need for rescue medication, improve lung function, and reduce exacerbations versus placebo, and improve measures of impairment and risk to a greater extent than non-steroidal anti-inflammatory medication. 4 ICSs are also generally well tolerated. 4 Nevertheless, concerns about long-term suppression of the hypothalamic-pituitary-adrenal (HPA) axis and an initial reduction in growth rates, which have been reported in many studies, persist; 5 consequently, some clinicians prefer not to use ICSs as first-line therapy. 6 Ciclesonide is an ICS pro-drug that is converted to its active form, desisobutyryl-ciclesonide, by esterases in the airways. 7 The efficacy and safety of ciclesonide has been widely demonstrated in children with asthma, 8e11 but few studies have assessed the doseeresponse relationships of several doses of the drug.
The RAINBOW study assessed the doseeresponse relationship with three doses of ciclesonide (40, 80 and 160 mg) given once daily in the evening in children with asthma. As some children are unable to use a metered dose inhaler (MDI) effectively, a secondary objective was to examine the impact of spacer use on the efficacy and safety of ciclesonide.
Methods

Study design and treatments
This was a double-blind, randomised, parallel-group study performed in 110 sites in Bulgaria, Germany, Hungary, Poland, Romania, Russia, South Africa, Spain and Ukraine. The study consisted of a run-in period (2e4 weeks) and a 12-week treatment period. At the start of the run-in (baseline) period, eligible patients discontinued their previous asthma medications and received a placebo MDI to practice their inhalation technique (one puff in the evening). The duration of the run-in period was sufficient to ensure washout of any previous ICSs. 12 Patients were then randomised into one of four treatment groups in a 2:2:2:1 ratio (ciclesonide 40 mg: ciclesonide 80 mg: ciclesonide 160 mg: placebo) by means of a computergenerated randomisation scheme. In addition, patients were randomly allocated (1:1) to inhale the study medication either with or without a spacer device (AeroChamber Plus Ò , Trudell Medical International, Ontario, Canada).
During the treatment period, patients inhaled one puff (40, 80 or 160 mg) of ciclesonide (ex-actuator; equivalent to 50, 100 and 200 mg ex-valve) or one puff of placebo in the evening. All treatments were administered via MDIs of identical appearance using hydrofluoroalkane134a (HFA134a) as the propellant. Salbutamol (100 mg/puff) was provided as rescue medication throughout the study; no other asthma medication was permitted. Patients visited the study sites weekly during the run-in (baseline) period and bi-weekly during the treatment period.
The study was conducted in accordance with Good Clinical Practice and the ethical principles of the Declaration of Helsinki. Written consent was obtained from the patients' parent(s) or legal guardian(s), and the protocol was approved by the appropriate Independent Ethics Committee or Institutional Review Boards.
Patients
Male and female outpatients aged 6e11 years with a history of persistent bronchial asthma 13 for !6 months were eligible for participation. Patients also had to be able to perform reproducible lung function tests and have an acceptable MDI inhalation technique. In the 30 days prior to study entry, patients could be treated with: rescue medication only; a constant dose of fluticasone propionate 200 mg/day or equivalent; or other controller medications. Randomisation criteria at the end of the run-in period included a mean peak expiratory flow (PEF) value (over last week) of 40e90% of the predicted value, as well as forced expiratory volume in 1 s (FEV 1 ) reversibility of !12% predicted after inhalation of 200e400 mg salbutamol. In addition, patients had to present asthma symptoms on at least 6 of the last 10 days of the baseline period, or use of at least eight puffs of rescue medication within the last 10 days of the baseline period.
Exclusion criteria included a history of near fatal asthma; a respiratory tract infection or asthma exacerbation within the last 30 days; two or more in-patient hospitalisations for asthma in the previous year; use of systemic glucocorticosteroids within 30 days prior to study entry or for >60 days in the previous 2 years.
Efficacy assessments
The highest of three daily morning and evening PEF measurements, performed with an electronic peak flow meter (AM2þ, VIASYS Healthcare GmbH, Hoechberg, Germany), was recorded in a diary, together with the use of rescue medication and daytime and night-time asthma symptoms, which were scored from 0 to 4 (0 equalled no asthma symptoms; 4 represented being awake most of the night or being unable to carry out daytime activities because of asthma).
Spirometry measurements (FEV 1 and PEF) were performed according to international guidelines at each clinic visit.
14,15 Percent-predicted values were calculated as previously described. 16 The patients' quality of life was assessed at the start and the end of the treatment period by using the standardised paediatric asthma quality of life questionnaire (PAQLQ[S]). 17 Treatment compliance was not formally monitored; however, patients and/or caregivers were told to report deviations from the intended treatment schedule in the diaries.
Primary and secondary efficacy variables
The primary variable was change in mean morning PEF (average over last week).
Key secondary variables were time (in days) to first loss of efficacy (LOE) and the percentage of days with asthma control. LOE was defined as worsening of asthma symptoms requiring a change in the patient's medication, other than rescue medication. Additional LOE criteria included: nocturnal awakenings, use of eight or more puffs of rescue medication, and decrease in morning PEF to <80% of the baseline value on 4 consecutive days.
Patients who fulfilled the LOE criteria were withdrawn and treated according to individual needs. Two different definitions of asthma control were evaluated: a day without asthma symptoms and without use of rescue medication, and a day without asthma symptoms, without use of rescue medication, with a morning PEF >80% predicted and with PEF fluctuation <15%.
Other efficacy variables included changes in: asthma symptom scores; asthma control defined on the basis of asthma symptoms and rescue medication; and PAQLQ(S) scores.
Safety and tolerability assessments
Adverse events (AEs) were assessed at each study visit by open questioning. Their nature, incidence, intensity and investigator's causality assessment were recorded. Physical examinations (including vital signs and laboratory tests) were performed at screening and at Week 12. Twenty-fourhour urine samples for analysis of free urinary cortisol and creatinine were collected at baseline and at the end of treatment. At investigational sites where a stadiometer was available, height was also measured at the start and end of the treatment period. Stadiometry is widely acknowledged as the most reliable means of measuring height and is recommended by the Food and Drug Administration (FDA) for studies assessing growth. 18 
Statistical analyses
The sample size of 1050 randomised patients (ciclesonide dose groups n Z 300 each; placebo n Z 150) was chosen to confirm superiority of ciclesonide 160 mg vs. placebo on the primary variable with 96% power. Similar power considerations were done for the other variables and pair-wise comparisons. Analyses of the efficacy variables were performed on a confirmatory basis and in hierarchical order, to assess superiority over placebo. To assess superiority of ciclesonide over placebo, the superiority of ciclesonide Table 1 Baseline demographics (ITT population). 160 mg vs. placebo in morning PEF was tested first (2.5% significance level, one-sided). Only if superiority was shown, the superiority test for ciclesonide 80 mg vs. placebo was performed. If the superiority of ciclesonide 80 mg was demonstrated, the key secondary variables were subjected to the confirmatory testing procedure in hierarchical order; otherwise, all subsequent analyses were considered exploratory. Details of other statistical tests are given in the online Supplementary material.
All analyses were performed on the intent-to-treat (ITT) population, which included all randomised patients who took at least one dose of study medication. For patients who discontinued treatment before Week 12, missing values were analysed using a last observation carried forward (LOCF) approach. To confirm the robustness of the ITT efficacy results, a per-protocol (PP) analysis was also performed and interpreted as a supportive analysis; only the results for the ITT analysis are reported. A restricted safety analysis was performed for urinary cortisol and body height data, in patients with valid measurements (e.g. those with corresponding creatinine values within the reference range and all measurements taken by the same device, respectively).
Results
Patients
In total, 1080 patients were randomised to treatment with ciclesonide 40 mg (n Z 304), ciclesonide 80 mg (n Z 312), ciclesonide 160 mg (n Z 313) or placebo (n Z 150). Of these, 1073 received study medication and comprised the ITT population.
Baseline demographics were similar across the treatment groups (Table 1) . Mean age was 8.4 years and most children (n Z 920) had either partly controlled or uncontrolled asthma at baseline. Patient disposition is shown in Fig. 1 . The number of withdrawals was slightly higher in the placebo group (24.7%) vs. the ciclesonide treatment groups a One patient was randomised to CIC 160 mg, but received CIC 40 mg. CIC, ciclesonide. 
Efficacy
Significant increases from baseline to week 12 in mean morning pre-bronchodilator diary PEF (L/min) were seen with all doses of ciclesonide, but not with placebo (ITT analysis, Fig. 2 ). All doses of ciclesonide were superior to placebo (p Z 0.012 for 40 mg; p Z 0.015 for 80 mg; p Z 0.003 for 160 mg) ( Table 2) . At week 12, there were no significant differences between any of the ciclesonide doses and placebo in the time to first LOE. The probability of not experiencing LOE (KaplaneMeier estimate) vs. placebo was: 72.8 (p Z 0.14) for ciclesonide 40 mg; 74.5 (p Z 0.09) for ciclesonide 80 mg and 73.2 (p Z 0.16) for ciclesonide 160 mg. In all treatment groups, the most frequent reasons for LOE were nocturnal awakenings and a decrease in morning PEF to <80% of the baseline value on 4 consecutive days.
The percentage of asthma control days (defined as days without symptoms and rescue medication) was approximately 15% at baseline, increasing to 58.1% in the placebo group and to approximately 80% in all ciclesonide groups (Fig. 3A) . The corresponding proportions of patients with an increase in the percentage of asthma control days were: 45.2% (ciclesonide 40 mg), 44.8% (ciclesonide 80 mg), 45.8% (ciclesonide 160 mg) and 32.6% (placebo); all treatment differences vs. placebo were statistically significant (p Z 0.0013, p Z 0.0014 and p Z 0.0006, respectively).
Data on the percentage of days with asthma control during treatment in patients whose asthma was partly controlled and uncontrolled at baseline are shown in Fig. 3B and C, respectively. A significant doseeresponse with ciclesonide was seen in patients whose asthma was Table 2 Changes from baseline in efficacy variables, within-treatment differences and differences between active drug and placebo (ITT population). uncontrolled at baseline (p Z 0.044); no doseeresponse effect was obvious in patients with partially controlled asthma at baseline.
When using a more stringent definition of asthma control (days without symptoms and rescue medication, morning PEF >80% predicted and PEF fluctuation <15%), the improvements seen in all treatment groups were smaller (Fig. 4A) . The proportions of patients who had an improvement in the percentage of asthma control days were: 52.6% (ciclesonide 40 mg), 53.5% (ciclesonide 80 mg), 53.7% (ciclesonide 160 mg) and 39.7% (placebo); all treatment differences vs. placebo were statistically significant (p Z 0.002, p Z 0.0006 and p Z 0.001, respectively). No doseeresponse was seen in patients with partly controlled asthma at baseline (Fig. 4B) , whereas a highly significant doseeresponse was noted in patients with previously uncontrolled asthma (p Z 0.0002) (Fig. 4C ).
All doses of ciclesonide showed significant improvements vs. placebo for FEV 1 (Table 2 ). Significant improvements vs. placebo were also seen for asthma symptoms (all ciclesonide doses) and rescue medication (ciclesonide 80 and 160 mg) ( Table 2) .
Quality of life
PAQLQ(S) scores were significantly improved from baseline to week 12 in all treatment groups, including placebo. All doses of ciclesonide significantly improved quality of life compared with placebo (Table 2 ).
Safety and tolerability
Adverse events
The incidence of treatment-emergent AEs was comparable in all treatment groups (ciclesonide 40 mg, 37.4%; 80 mg, 35.6%; 160 mg, 32.9%; placebo, 32.9%); most AEs were mild or moderate in severity.
The most frequently reported AEs were upper respiratory tract infections (ciclesonide 40 mg, 5.9%; 80 mg, 6.4%; 160 mg, 5.2%; placebo, 3.4%) and pharyngitis (ciclesonide 40 mg, 4.6%; 80 mg, 5.8%; 160 mg, 5.2%; placebo, 4.8%). In total, 14 patients withdrew due to AEs, as follows: asthma (n Z 4), bronchitis (n Z 1), sinusitis (n Z 3), wheezing (n Z 2), pyrexia (n Z 1), rhinitis (n Z 1), upper respiratory tract infection (n Z 1) and lower respiratory tract infection (n Z 1). Overall, the incidence of AEs considered to be related to study medication was very low (0.7%). The total incidence of serious AEs was also low (1.1%) and comparable between all treatment groups; none were considered to be related to study medication and there were no deaths during the study. AEs of interest are listed in the online Supplementary material.
HPA-axis function and body height
At study end, there were no statistically significant changes from baseline in urinary cortisol levels (adjusted for creatinine) between ciclesonide and placebo (Fig. 5a ).
Body height significantly increased from baseline in all treatment groups (p < 0.0001) (Fig. 5b ). There were no significant differences in growth rate between any of the doses of ciclesonide and placebo (p > 0.05).
Impact of spacer use
No differences were observed between the spacer and nonspacer subgroups for any of the efficacy or safety outcomes (Table 3 ; Fig. 5a and b) .
Discussion
The main findings in the present study were that: 1) low daily doses of ciclesonide were clinically significantly more effective than placebo for the vast majority of outcomes; 2) clinically effective doses were without any detectable adverse systemic effects; 3) no apparent doseeresponse relationship was demonstrated in the overall population, but significant doseeresponse relationships were seen for the two definitions of asthma control in patients with uncontrolled asthma at baseline; and 4) use of a spacer did Figure 5 Change from baseline in A) urinary cortisol adjusted for creatinine (HL point estimate, restricted safety analysis) and B) body height measured by stadiometry (restricted safety analysis) for the total population and spacer subgroups. a Two-sided p-value (within-treatment differences) significance level 5% (based on analysis of covariance). b Percentage of days with asthma control was based on use of rescue medication and asthma symptoms. c Two-sided p-value (within-treatment differences) significance level 5% (based on Wilcoxon's signed rank test, modification by Pratt). CIC, ciclesonide; FEV 1 , forced expiratory volume in 1 s; HL, HodgeseLehmann; ITT, intent-to-treat; LS, least squares; PEF, peak expiratory flow; SEM, standard error of the LS mean.
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not influence the clinical effect or the risk of adverse systemic effects of the treatment.
International guidelines recommend that the measure of "asthma control" should reflect the extent to which the manifestations of asthma have been reduced or removed by treatment. 19 In addition, rather than assessing a single outcome, a combination of outcomes should be used as this is more likely to be clinically relevant and show differences between treatments. 19 In line with this, the current study used a multi-component definition for asthma control based on a combination of the following variables: asthma symptoms, use of rescue medication, morning PEF and PEF fluctuation. However, when all four variables were included, the percentage of asthma control days at baseline was very low (in fact the median for all groups was zero), indicating that this definition was perhaps too stringent. With the more widely used definition, based on asthma symptoms and rescue medication, the median percentage of asthma control days at baseline increased to approximately 15% and effect of treatment was also much more pronounced, indicating that the PEF criteria used markedly affected the results for asthma control. This is in agreement with the findings in an earlier study with ciclesonide and fluticasone propionate using the same control definitions in children with asthma. The proportions of patients with asthma control post-treatment were approximately 70e80% for the less stringent definition and approximately 30e45% for the definition that included four criteria. 11 These figures are similar to those found in the present study. As the duration of both studies was only 3 months and several outcomes require long periods of treatment before the maximum effect is achieved, 19 no conclusions can be made about the proportion of patients who will achieve control with continued treatment.
The criteria for the LOE endpoint were based on the definitions of asthma control and early indications of loss of control suggested in the various guidelines and papers on asthma control, 2, 3, 20, 21 which suggest that increases in symptoms, nocturnal awakenings and increases in the need for rescue medication are early indications of loss of control. Although our definitions of the LOE endpoints have not been formally validated, the literature does suggest that changes in the included parameters reflect changes in asthma control. 4, 20, 22 The magnitude of the placebo response for the asthma control endpoint was relatively large. Significant placebo responses have been reported in other studies in patients with asthma, including children. 23e25 The exact reason for this is not known. Some regression towards the mean would be expected to occur because all included patients must be somewhat uncontrolled to be included in the study. In addition, it has been shown that raising patients' optimism about treatment enhances the placebo effect for patientreported outcomes, but not lung function tests, whereas it does not affect the response to active treatment for either measure. 26 In agreement with this the placebo response in the present study was more pronounced for subjective than objective outcomes.
Normally, the doseeresponse relationships for ICS are rather shallow and most studies fail to demonstrate significant doseeresponse effects. 27e29 In agreement with this, no significant doseeresponse was seen in the overall population in our study. Such findings sometimes lead to the erroneous conclusion that there will be no important clinical benefit of increasing the dose of ICS. However, as a significant doseeresponse was seen in the patients with uncontrolled asthma at baseline, our data suggest that many such patients would benefit from higher doses of ICS. To the best of our knowledge, this is the first study to assess the influence of the level of asthma control prior to treatment on the likelihood of demonstrating significant doseeresponse relationships.
The sample size for the current study was based, in part, on the number of patients required to demonstrate a significant treatment effect on LOE. However, in agreement with clinical trial recommendations, 20 the LOE criteria were mainly designed to minimise the risk for the patients (a placebo arm was included) rather than to assess efficacy. This may have influenced the findings with LOE. Other possible contributing factors to the finding could be that the most common reason for LOE was nocturnal awakening, regardless of cause (i.e. some may not have been due to asthma) and the previously mentioned rather low morning PEF values from the patients' diaries, which were distinctly lower than PEF values from spirometry at the clinic (data not shown). This, in combination with the findings from a recent study showing that morning PEF responds rather slowly to treatment with montelukast or a fluticasoneesalmeterol combination in children, 30 may have contributed to the relatively high rates of withdrawals due to LOE and lack of differences between treatments in the study.
The statistically significant effects of ciclesonide on other outcomes, including lung function (FEV 1 ), asthma symptom score and PAQLQ(S) were consistent with the findings in other paediatric studies with ciclesonide.
8e11
The low level of adverse local effects or systemic effect of ciclesonide on the HPA-axis is in agreement with earlier findings in children.
8e11,31e33 Daily doses up to 320 mg have been shown to not adversely affect on lower-leg growth or urinary cortisol excretion 8, 31, 33 and comparative studies with other ICS have found that mg for mg, ciclesonide causes significantly less suppression of urinary cortisol excretion and lower-leg growth rate than fluticasone propionate. 31 In a previous study, it was found that treatment with ciclesonide (in doses up to 160 mg per day) did not adversely affect growth over 1 year. 33 As ciclesonide did not significantly improve lung function vs. placebo, it was suggested that the lack of effect on growth could also have been due to poor compliance, although canister weights and diary recordings of medication intake suggested that this was not the case. 33e36 In contrast, the present study found significant clinical effects, but still no adverse effect on stature growth over 3 months. As earlier studies have consistently reported that the effect of ICS is more marked at the beginning of treatment 5 and height in the current study was measured by standardised stadiometry, we believe that any clinically important differences in growth between treatments would have been detected. In agreement with this, an earlier study of 12 weeks' duration found a significantly higher growth rate with ciclesonide 160 mg/day (1.18 cm) than with budesonide 400 mg/day (0.70 cm). 9 A spacer device reduces oropharyngeal deposition of ICS and the associated risk of local side effects. Many spacers also increase drug deposition in the intrapulmonary airways to some extent and spacers are generally easier to use than a propellant MDI (pMDI) alone. 2 As local adverse effects are rare during ciclesonide treatment and its pMDI delivers a high fraction of drug to the intrapulmonary airways, the use of a spacer would not be expected to affect the clinical or systemic effects to any significant extent in patients who can use the pMDI correctly. In agreement with this, the use of an AeroChamber Plus Ò spacer in the current study did not affect the efficacy or safety results. This finding suggests that the two modes of administration can be used interchangeably without adjustment of dose in children with good inhalation technique. In addition, children with a poor pMDI inhalation technique can start spacer treatment with the usual recommended doses for the pMDI.
In conclusion, ciclesonide 40e160 mg once daily is an effective and well-tolerated treatment for persistent asthma in children aged 6e11 years. The efficacy and safety of the treatment was not affected by use of a spacer.
